A device for fatigue, Raynaud's, and quality of life in scleroderma
Part of Heart & circulation, Skin clinical trials.
This trial tests if a device called Apollo can help reduce fatigue and Raynaud's symptoms and improve quality of life in people with scleroderma (systemic sclerosis). You would use the device at home and track your symptoms using a smartphone app.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with systemic sclerosis (scleroderma) and have a positive ANA test.
- You experience fatigue that scores at least 55 on a standard fatigue questionnaire.
- You have Raynaud's phenomenon with a severity score of 40 or higher.
- You have a smartphone (iPhone or Android) and use it regularly.
- You are willing to keep your current medications stable for 4 weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether people with systemic sclerosis (scleroderma) and pulmonary arterial hypertension (PAH) can safely monitor their heart health at home using a smartphone or other internet-connected device. If you have PAH and are comfortable using technology, this trial may help make care more convenient.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This study tests whether a person's own fat cells (processed into regenerative cells) can be injected into the hands to improve hand function and reduce skin thickening in systemic sclerosis (scleroderma). It’s designed for people whose hand problems are significant but not too severe.
This trial tests whether stem cells from umbilical cord blood can help treat systemic sclerosis (scleroderma). The goal is to see if this treatment can improve skin thickening and overall symptoms for people who haven't had success with standard therapies.
This study tests a new medicine (called GB261) given as an infusion for people with systemicsclerosis (scleroderma) that affects the skin widely. The goal is to see if it can reduce skin thickening and improve symptoms.
This study tests a special patch with tiny needles that deliver botulinum toxin (botox) into the skin to treat Raynaud's symptoms in people with scleroderma. It may help reduce pain and improve blood flow in fingers and toes.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.